©2025 Stanford Medicine
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
Not Recruiting
Trial ID: NCT02654483
Purpose
Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
Official Title
A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients
Stanford Investigator(s)
Albert Sean Chiou, MD, MBA
Clinical Associate Professor, Dermatology
Eligibility
Inclusion Criteria:
* Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus
Exclusion Criteria:
* Chronic liver or renal disease
Intervention(s):
drug: VPD-737
drug: VPD-737
other: Placebo
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Claudia Teng
725-7152